Technology Transfer News
The current Coronavirus pandemic has scientists worldwide collaborating extensively to learn about the virus and develop vaccines as well as therapeutics. Together with scientific and industrial partners including the Paul Scherrer Institute, our spin-off leadXpro has developed a method to provide the research and development community with SARS-CoV-2 M protein. This M protein that is an important part of the virus capsule is a potential target for drugs against the virus. We are happy to invite interested parties wishing to receive protein to contact leadXpro.
The current pandemic is also having a severe impact on Switzerland as a business loca-tion. That is why it is particularly important to invest in innovation now. With this in mind, “Switzerland Innovation” Foundation is launching its first major call for proposals to-gether with renowned partners from the Swiss economy. Funding will be provided for in-novation projects that address the most pressing problems of our time.
The PSI Spin-Off Araris Biotech AG is one of the 10 winners of this year’s Venture Leaders Life Science award
As a winner, Araris will take part in the Swiss Biotech Day 2020 and a one-week roadshow to Boston, where Araris along with the other Venture Leaders will be pitching to key US investors and meeting leaders and experts of the biotech and medtech industries. Boston is one of the world’s major life sciences hubs and the ideal springboard for ambitious startups on their way to global expansion.
For the third time, Switzerland Innovation Park Innovaare in Villigen/AG is hosting the call for proposals for high-tech business ideas that incorporate accelerator technologies into their products.
Anaxam is a technology transfer center created as a collaboration between PSI, the FHNW, the SNI and the Kanton of Aargau. Created to provide simplified access for industry to the large research facilities at PSI and focused on delivering services to support Advanced Manufacturing, both in the improvement of existing products as well as with manufacturing processes. ANAXAM has Officially Launched today 2019.12.01.
Today, PARK INNOVAARE steps into a new era. Accompanied by more than 200 guests including partners, shareholders, and key politicians, scientists and entrepreneurs, PARK INNOVAARE broke the ground to the construction of its new innovation campus. An investment of 155 CHF million by CPV/CAP Coop Pension Fund has brought this construction project to fruition
Araris Biotech AG (a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich) announced today the closing of an oversubscribed seed financing round of CHF 2.5 million with participation of Swiss investors Redalpine, Schroder Adveq and VI Partners. The proceeds will be used to develop a pipeline of proprietary antibody-drug conjugates (ADCs)
After an intensive round of negotiations, Park Innovaare concluded an investment agreement with CPV/CAP Pensionskasse Coop for the realization of the new buildings. With this agreement, Park Innovaare has come another step closer to realizing its goal: a state-of-the-art infrastructure of about 38’000 sqm next to the Paul Scherrer Institute PSI that is ideal for industrial R&D projects.
Debiopharm – a Swiss pharma company that has licensed-in one of PSIs developments -a compound with high potential for cancer diagnosis & therapy has been nominated for the “2019/2020 Swiss Biotech Sucess Stories Awards”